

CITATION REPORT

List of articles citing

Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial

DOI: 10.1016/j.ajo.2013.05.002

American Journal of Ophthalmology, 2013, 156, 478-486.e1.

Source: <https://exaly.com/paper-pdf/55918374/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
85	Use of Methotrexate for the Treatment of Ocular Inflammation and Uveitis. <i>Journal of Pharmacovigilance</i> , 2013 , 01,		1
84	Two functional variants of IRF5 influence the development of macular edema in patients with non-anterior uveitis. <i>PLoS ONE</i> , 2013 , 8, e76777	3.7	3
83	[Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists]. <i>Ophthalmologe</i> , 2014 , 111, 1033-40	1.6	5
82	[Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis (as of 02. 07. 2014)]. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2014 , 231, 929-36	0.8	1
81	[Uveitis in multiple sclerosis : Overview and perspectives]. <i>Ophthalmologe</i> , 2014 , 111, 733-9	1.6	5
80	[Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014]. <i>Ophthalmologe</i> , 2014 , 111, 740-8	1.6	4
79	A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1651-66	5.4	4
78	A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. <i>Ophthalmology</i> , 2014 , 121, 1863-70	7.3	73
77	Uveitic macular edema: a stepladder treatment paradigm. <i>Clinical Investigation</i> , 2015 , 5, 509-517		4
76	Clinical trials in noninfectious uveitis. <i>International Ophthalmology Clinics</i> , 2015 , 55, 79-110	1.7	13
75	Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis. <i>Journal of Ophthalmic and Vision Research</i> , 2015 , 10, 469-80	1.2	35
74	Effect of interferon α in cystoid macular edema due to intraocular infection. <i>European Journal of Ophthalmology</i> , 2015 , 25, 431-6	1.9	11
73	Functional outcome of macular edema in different retinal disorders. <i>Progress in Retinal and Eye Research</i> , 2015 , 48, 119-36	20.5	22
72	[Uveitic macular edema]. <i>Journal Francais DrOphtalmologie</i> , 2015 , 38, 74-81	0.8	5
71	Therapeutic options for the treatment of non-infectious uveitis. <i>Expert Review of Ophthalmology</i> , 2015 , 10, 359-373	1.5	2
70	Biological response modifiers in the treatment of noninfectious uveitis. <i>International Ophthalmology Clinics</i> , 2015 , 55, 19-36	1.7	2
69	[Guideline of the Professional Association of German Ophthalmologists eV and the German Ophthalmology Society: Guideline No. 24a: Uveitis intermedia (July 2014)]. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2015 , 232, 79-84	0.8	0

68	Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile. <i>Current Drug Safety</i> , 2016 , 11, 47-54	1.4	3
67	Acute onset of fingolimod-associated macular edema. <i>American Journal of Ophthalmology Case Reports</i> , 2016 , 4, 67-70	1.3	4
66	Uveitic macular edema. <i>Eye</i> , 2016 , 30, 1277-1292	4.4	57
65	Review of the latest systemic treatments for chronic non-infectious uveitis. <i>Expert Review of Ophthalmology</i> , 2016 , 11, 111-133	1.5	2
64	Biologicals in Uveitis. 2016 , 33-42		
63	Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. <i>Ocular Immunology and Inflammation</i> , 2017 , 25, 215-220	2.8	28
62	Multiple Sclerosis-related Uveitis: Does MS Treatment Affect Uveitis Course?. <i>Ocular Immunology and Inflammation</i> , 2017 , 25, 302-307	2.8	17
61	Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. <i>Expert Review of Ophthalmology</i> , 2017 , 12, 313-319	1.5	10
60	Multiple sclerosis-associated uveitis. <i>Expert Review of Ophthalmology</i> , 2017 , 12, 57-67	1.5	3
59	PERIPHERAL RETINOSCHISIS IN INTERMEDIATE UVEITIS. <i>Retina</i> , 2017 , 37, 2167-2174	3.6	10
58	Interferon-alpha2a and Systemic Corticosteroid in Monotherapy in Chronic Uveitis: Results of the Randomized Controlled BIRDFERON Study. <i>American Journal of Ophthalmology</i> , 2017 , 177, 182-194	4.9	22
57	Multiple Sclerosis-Associated Uveitis. <i>Ocular Immunology and Inflammation</i> , 2017 , 25, 299-301	2.8	10
56	[Therapeutic Concepts for Treatment of Patients with Non-infectious Uveitis Biologic Disease Modifying Antirheumatic Drugs]. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2018 , 235, 553-561	0.8	1
55	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. <i>Ophthalmology</i> , 2018 , 125, 757-773	7.3	97
54	Traitements systémiques des uvéites. <i>Revue De Medecine Interne</i> , 2018 , 39, A37-A44	0.1	
53	[Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel]. <i>Revue De Medecine Interne</i> , 2018 , 39, 687-698	0.1	3
52	[Intraocular inflammation in multiple sclerosis]. <i>Ophthalmologe</i> , 2018 , 115, 531-542	1.6	3
51	A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis. <i>Ophthalmology and Therapy</i> , 2018 , 7, 1-17	5	6

50	The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study. <i>Graefers Archive for Clinical and Experimental Ophthalmology</i> , 2018 , 256, 1985-1992	3.8	15
49	Recent progress in the treatment of uveitic macular edema. <i>Expert Review of Ophthalmology</i> , 2019 , 14, 227-236	1.5	2
48	Choroidal changes after intravitreal injection of interferon alpha-2b. <i>Experimental Biology and Medicine</i> , 2019 , 244, 1144-1148	3.7	
47	Bilateral Anterior and Intermediate Uveitis with Occlusive Vasculitis as Sole Manifestation of Relapse in Multiple Sclerosis. <i>Case Reports in Ophthalmological Medicine</i> , 2019 , 2019, 8239205	0.7	4
46	Treatment of Non-infectious Uveitis. 2019 ,		
45	Expert opinion on the use of biological therapy in non-infectious uveitis. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 477-490	5.4	29
44	The Effectiveness of Pharmacological Agents for the Treatment of Uveitic Macular Edema (UMO): A Systematic Review. <i>Ocular Immunology and Inflammation</i> , 2019 , 27, 658-680	2.8	1
43	Update in treatment of uveitic macular edema. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 667-680	4.4	22
42	New therapies in development for the management of non-infectious uveitis: A review. <i>Clinical and Experimental Ophthalmology</i> , 2019 , 47, 396-417	2.4	26
41	Visual and Clinical Outcome of Macular Edema Complicating Pediatric Noninfectious Uveitis. <i>American Journal of Ophthalmology</i> , 2019 , 202, 72-78	4.9	11
40	Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review. <i>Ocular Immunology and Inflammation</i> , 2021 , 29, 566-571	2.8	2
39	Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. <i>Current Opinion in Ophthalmology</i> , 2019 , 30, 138-150	5.1	30
38	The Results of Interferon-Alpha Treatment in Behçet Uveitis. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 498-504	2.8	10
37	Inflammatory and Infectious Ocular Disorders. <i>Retina Atlas</i> , 2020 ,	0	0
36	EVALUATION OF THE EFFECT OF TOPICAL INTERFERON α 2b AS A COMPLEMENTARY TREATMENT OF MACULAR EDEMA OF PATIENTS WITH DIABETIC RETINOPATHY: A Double-Blind Placebo-Controlled Randomized Clinical Trial Study. <i>Retina</i> , 2020 , 40, 936-942	3.6	4
35	VASOPROLIFERATIVE TUMORS IN INTERMEDIATE UVEITIS. <i>Retina</i> , 2020 , 40, 1765-1773	3.6	4
34	Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1299-1306	5.3	7
33	The current status of biological treatment for uveitis. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 787-811	5.1	4

32	Insights into multiple sclerosis-associated uveitis: a scoping review. <i>Acta Ophthalmologica</i> , 2021 , 99, 592-603	3.03	1
31	Comparison of conventional immunosuppressive drugs versus anti-TNF- α agents in non-infectious non-anterior uveitis. <i>Journal of Autoimmunity</i> , 2020 , 113, 102481	15.5	8
30	Recent advances in the management of non-infectious posterior uveitis. <i>International Ophthalmology</i> , 2020 , 40, 3187-3207	2.2	1
29	A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis. <i>PLoS ONE</i> , 2020 , 15, e0227524	3.7	3
28	Medical Therapy of Uveitic Macular Edema: Biologic Agents. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 1239-1250	2.8	4
27	[Guidelines nr. 24a intermediate uveitis]. <i>Ophthalmologe</i> , 2021 , 118, 16-30	1.6	0
26	Biologic Drugs for the Treatment of Noninfectious Uveitis. <i>Asia-Pacific Journal of Ophthalmology</i> , 2021 , 10, 63-73	3.5	1
25	Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease. <i>Ophthalmologica</i> , 2021 , 244, 418-450	3.7	1
24	Update on the Management of Uveitic Macular Edema. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
23	Multiple Sclerosis. 2016 , 851-861		1
22	Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. <i>Medicina Clinica</i> , 2020 , 155, 220.e1-220.e12	1	2
21	A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. <i>Health Technology Assessment</i> , 2017 , 21, 1-170	4.4	20
20	Interleukins and cytokine biomarkers in uveitis. <i>Indian Journal of Ophthalmology</i> , 2020 , 68, 1750-1763	1.6	10
19	Macular Edema. 2016 , 443-454		2
18	Macular Edema. 2017 , 343-354		1
17	Novel Use of Existing Imaging Modalities to Assess Intraocular Inflammation. 2018 , 151-163		
16	Interferons and Intravenous Immunoglobulin. 2019 , 113-129		
15	Intermediate Uveitis. <i>Retina Atlas</i> , 2020 , 77-91	0	

14	A Cell Penetrating Peptide from Type I Interferon Protects the Retina in a Mouse Model of Autoimmune Uveitis.		
13	Approaches to Medical Therapy. 2020 , 73-102		
12	Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. <i>Medicina Clinica (English Edition)</i> , 2020 , 155, 220.e1-220.e12	0.3	
11	Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022 ,	2.6	1
10	Biologics in the Treatment of Uveitis.. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2022 , 239,	0.8	0
9	Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.. <i>Ocular Immunology and Inflammation</i> , 2022 , 1-8	2.8	0
8	Intermediate Uveitis: A Review. <i>Ocular Immunology and Inflammation</i> , 1-20	2.8	
7	Assoziation der verschiedenen Uveitisformen mit entzündlich rheumatischen Erkrankungen und ihre Therapie. 2022 , 81, 667-681		0
6	Aqueous Humor FactorsTPredictive Effects in Treating Refractor Macular Edema: An Overview.		0
5	A Systematic Review of Clinical Trials in Uveitis: Lessons Learned. 1-8		0
4	A review of patient-reported outcome measures used in uveitis. 2022 ,		0
3	Pathogenesis and current therapies for non-infectious uveitis.		0
2	Assoziation der verschiedenen Uveitisformen mit entzündlich rheumatischen Erkrankungen und ihre Therapie. 2023 , 120, 223-236		0
1	Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. 2023 , 22, 103312		0